PTG-007 (cell therapy for diabetes)

2024: Product Announcement

On September 9, 2024, the Polish biotechnology company PolTREG announced the development of a cell therapy for PTG-007 designed to treat type 1 diabetes. The use of the method provides clinical remission for up to 12 years, and in some patients there is no need for insulin for a period of 18 to 24 months.

Diabetes the first type (insulin-dependent, juvenile or pediatric) is characterized by insufficient production of insulin in the body. Such people require daily administration of insulin to regulate the amount of glucose in their blood. According to World Organization health care (WHO), in 2017 there were about 9 million people with type 1 diabetes worldwide; most of them lived in high-income countries. The cause of this disease is unknown, and prevention measures have not been developed.

𝓲

clinicaltrialsarena

We believe that PTG-007 therapy can save many patients with type 1 diabetes from the lifelong need to give frequent insulin injections and from serious long-term complications of this disease, says Professor Piotr Trzonkowski, CEO of PolTREG.

It is noted that the best results are demonstrated by patients receiving PTG-007 therapy in combination with standard anti-CD20 treatment (rituximab). The researchers analyzed more than 700 indicators of cardiac function, microcirculation, kidneys, liver, endocrine system, fertility, etc. No deterioration was observed in patients treated with PTG-007 cell therapy compared to standard treatment. In addition, no serious side effects were found. Thus, PTG-007 therapy in the future can improve the quality of life of millions of people with type 1 diabetes.^[1]

Notes